BR0116762A - Análogos tacrolimus neurotróficos, métodos e uso dos mesmos - Google Patents
Análogos tacrolimus neurotróficos, métodos e uso dos mesmosInfo
- Publication number
- BR0116762A BR0116762A BR0116762-6A BR0116762A BR0116762A BR 0116762 A BR0116762 A BR 0116762A BR 0116762 A BR0116762 A BR 0116762A BR 0116762 A BR0116762 A BR 0116762A
- Authority
- BR
- Brazil
- Prior art keywords
- neurotrophic
- tacrolimus
- methods
- analogues
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Packages (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"ANáLOGOS TACROLIMUS NEUROTRóFICOS, MéTODOS E USO DOS MESMOS". Os derivados tacrolimus têm altos níveis de atividade neurotrófica e baixos níveis de atividade imunossupressora. Estes compostos são úteis como agentes neurotróficos, particularmente, para prevenir ou tratar ferimento/disfunção neuronal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25850000P | 2000-12-29 | 2000-12-29 | |
PCT/US2001/050419 WO2002053159A1 (en) | 2000-12-29 | 2001-12-31 | Neurotrophic tacrolimus analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0116762A true BR0116762A (pt) | 2004-08-10 |
Family
ID=22980816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0116762-6A BR0116762A (pt) | 2000-12-29 | 2001-12-31 | Análogos tacrolimus neurotróficos, métodos e uso dos mesmos |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1353671A4 (pt) |
JP (1) | JP2004527472A (pt) |
KR (2) | KR20070030331A (pt) |
CN (1) | CN1293877C (pt) |
AR (1) | AR035411A1 (pt) |
AU (1) | AU2002231277B2 (pt) |
BR (1) | BR0116762A (pt) |
CA (1) | CA2433384A1 (pt) |
CZ (1) | CZ20032060A3 (pt) |
HU (1) | HUP0302521A3 (pt) |
IL (1) | IL156664A0 (pt) |
MX (1) | MXPA03005941A (pt) |
NO (1) | NO20032913D0 (pt) |
NZ (1) | NZ527209A (pt) |
PL (1) | PL366301A1 (pt) |
RU (1) | RU2288716C2 (pt) |
WO (1) | WO2002053159A1 (pt) |
ZA (1) | ZA200305806B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003901023A0 (en) * | 2003-03-04 | 2003-03-20 | Fujisawa Pharmaceutical Co., Ltd. | New use |
CA2554045A1 (en) * | 2004-01-20 | 2005-07-28 | Astellas Pharma Inc. | Method for treating erectile dysfunction |
EP1810675A1 (en) * | 2006-01-18 | 2007-07-25 | Institut Curie | Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421 |
JP2009102226A (ja) * | 2006-02-14 | 2009-05-14 | Meiji Milk Prod Co Ltd | 脊髄損傷治療剤 |
JP5878015B2 (ja) * | 2008-07-23 | 2016-03-08 | ノバルティス アーゲー | スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用 |
JP2015511242A (ja) * | 2012-02-23 | 2015-04-16 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル) | 病変性前庭障害の治療に使用するカルシニューリン阻害剤 |
GB201309375D0 (en) * | 2013-05-24 | 2013-07-10 | Chronos Therapeutics Ltd | Medical methods and compounds for medical use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2799208B2 (ja) * | 1987-12-09 | 1998-09-17 | フアイソンズ・ピーエルシー | マクロ環状化合物 |
GR1001225B (el) * | 1989-09-14 | 1993-06-30 | Fisons Plc | Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους. |
US5541193A (en) | 1991-09-05 | 1996-07-30 | Abbott Laboratories | Heterocycle-containing macrocyclic immunomodulators |
GB9202196D0 (en) * | 1992-02-01 | 1992-03-18 | Fisons Plc | Method of treatment |
GB9218027D0 (en) * | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
GB9917158D0 (en) * | 1999-07-21 | 1999-09-22 | Fujisawa Pharmaceutical Co | New use |
-
2001
- 2001-12-27 AR ARP010106058A patent/AR035411A1/es unknown
- 2001-12-31 BR BR0116762-6A patent/BR0116762A/pt not_active Application Discontinuation
- 2001-12-31 CA CA002433384A patent/CA2433384A1/en not_active Abandoned
- 2001-12-31 PL PL01366301A patent/PL366301A1/xx not_active Application Discontinuation
- 2001-12-31 HU HU0302521A patent/HUP0302521A3/hu unknown
- 2001-12-31 IL IL15666401A patent/IL156664A0/xx unknown
- 2001-12-31 RU RU2003123493/15A patent/RU2288716C2/ru not_active IP Right Cessation
- 2001-12-31 JP JP2002554109A patent/JP2004527472A/ja not_active Ceased
- 2001-12-31 CN CNB018228860A patent/CN1293877C/zh not_active Expired - Fee Related
- 2001-12-31 AU AU2002231277A patent/AU2002231277B2/en not_active Ceased
- 2001-12-31 CZ CZ20032060A patent/CZ20032060A3/cs unknown
- 2001-12-31 KR KR1020077003889A patent/KR20070030331A/ko not_active Application Discontinuation
- 2001-12-31 NZ NZ527209A patent/NZ527209A/en unknown
- 2001-12-31 EP EP01991558A patent/EP1353671A4/en not_active Withdrawn
- 2001-12-31 MX MXPA03005941A patent/MXPA03005941A/es active IP Right Grant
- 2001-12-31 WO PCT/US2001/050419 patent/WO2002053159A1/en active IP Right Grant
- 2001-12-31 KR KR1020037008787A patent/KR100794204B1/ko not_active IP Right Cessation
-
2003
- 2003-06-24 NO NO20032913A patent/NO20032913D0/no not_active Application Discontinuation
- 2003-07-28 ZA ZA2003/05806A patent/ZA200305806B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2002231277B2 (en) | 2006-11-30 |
IL156664A0 (en) | 2004-01-04 |
ZA200305806B (en) | 2005-01-26 |
EP1353671A4 (en) | 2004-07-14 |
CN1538843A (zh) | 2004-10-20 |
HUP0302521A2 (hu) | 2003-11-28 |
KR20040007431A (ko) | 2004-01-24 |
CA2433384A1 (en) | 2002-07-11 |
EP1353671A1 (en) | 2003-10-22 |
JP2004527472A (ja) | 2004-09-09 |
MXPA03005941A (es) | 2005-02-14 |
NO20032913D0 (no) | 2003-06-24 |
NZ527209A (en) | 2005-09-30 |
PL366301A1 (en) | 2005-01-24 |
KR100794204B1 (ko) | 2008-01-14 |
WO2002053159A1 (en) | 2002-07-11 |
AR035411A1 (es) | 2004-05-26 |
CZ20032060A3 (cs) | 2004-01-14 |
CN1293877C (zh) | 2007-01-10 |
RU2288716C2 (ru) | 2006-12-10 |
HUP0302521A3 (en) | 2007-03-28 |
KR20070030331A (ko) | 2007-03-15 |
RU2003123493A (ru) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
NO953093D0 (no) | Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler | |
ES2133270T3 (es) | Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna. | |
PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
ATE468889T1 (de) | Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut | |
ITMI961152A0 (it) | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele | |
BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
BR0207775A (pt) | Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização | |
BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
TR200200883T2 (tr) | 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları | |
DE69830095D1 (de) | Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe | |
TR200400526T4 (tr) | Göz kurumasının tedavisi için lipoksin A4 ve analogları | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
NO20035025L (no) | Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. | |
BR9708114A (pt) | Análogos xantona para o tratamento de doenças infecciosas. | |
BR0316296A (pt) | Compostos lapacone e seus métodos de uso | |
BR0015416A (pt) | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos | |
ES2192832T3 (es) | Uso de compuestos macrolidos para tratar glaucoma. | |
ES2167544T3 (es) | Dioxidos de benzotiazina como antagonistas de la endotelina. | |
PT932613E (pt) | Expressao de bloqueio de factoes de virulencia em s. aureus | |
BR9908427A (pt) | Composições farmacêuticas e uso das mesmas | |
SE9604348D0 (sv) | Användning av hydroxyguanidiner | |
BR0116762A (pt) | Análogos tacrolimus neurotróficos, métodos e uso dos mesmos | |
EA199800666A1 (ru) | Применение lhrh-аналога или комбинации lhrh-аналогов и антиэстрогена с селективным по отношению к тканям эстрогенным действием для лечения гинекологических нарушений |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO. LTD. |
|
B25D | Requested change of name of applicant approved |
Owner name: ASTELLAS PHARMA INC. (JP) Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |